JAGSNPHARMBSEJagsonpal Pharmaceuticals LtdHighPositive
Announced Mon, 25 May · 13:21 IST

Centrum Broking Ltd ("Manager to the Buyback") has submitted to BSE a copy of Post Buyback Public Announcement for the attention of Equity Shareholders / Beneficial Owners of Equity Shares ....

Buyback Premium Above 10pctCorporate Actions View source PDF

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.0%1-day move
₹209.00
prior close
₹205.33
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0+0.1-0.2-0.2-1.0-1.0-1.4-3.3-3.6-1.4+0.2+6.7+10.0
Up moveDown movePending
AI summary

Centrum Broking Ltd, as Manager to the Buyback, has submitted the Post Buyback Public Announcement for Jagsonpal Pharmaceuticals Ltd. The buyback offer, which had a Letter of Offer dated May 06, 2026, opened on May 08, 2026 and closed on May 14, 2026. The Post Buyback Public Announcement was published on May 25, 2026, within 2 working days from completion of payment consideration to eligible shareholders. The announcement was published in Financial Express (English) and Jansatta (Hindi) newspapers. The buyback was conducted under SEBI (Buy-back of Securities) Regulations, 2018 for fully paid-up equity shares of face value ₹2 each.

Likely market impact

The completion of this buyback means the company has returned capital to shareholders who tendered shares. The market typically views completed buybacks positively as they indicate management confidence in undervaluation. Shareholders who participated received the buyback price.